Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

483.49 -1.25 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
The Ultimate Biotech Stock to Buy With $500 Right Now
Via The Motley Fool
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions. 
Via Benzinga
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain
The company says there was variability among placebo responses at various sites. 
Via Investor's Business Daily
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals' drug reduced back pain significantly. 
Via Investor's Business Daily
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Got $500? 1 Biotech Stock to Buy and Hold Forever
Via The Motley Fool
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Unstoppable Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments. 
Via Benzinga
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Via Benzinga
2 No-Brainer Stocks to Buy Before the End of 2024
Via The Motley Fool
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
It’s Been A Tough Month For Healthcare Stocks
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS